- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Paclitaxel, Radium Ra 223 Dichloride, Single Photon Emission Computed Tomography
- Procedure · Other · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–81
of 81
matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single-photon emission computed tomography (SPECT)/Computerized tomography (CT) Clear all
- Conditions
- Prostate Cancer, Advanced Cancer
- Interventions
- Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617
- Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Etoposide, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate, Radioconjugate, Dual X-ray Absorptiometry, Gallium Ga 68-PSMA-617, Positron Emission Tomography, Single Photon Emission Computed Tomography
- Procedure · Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Neuroendocrine Tumors
- Interventions
- 3-[18F]Fluoro-para-hydroxyphenethylguanidine, [123I] metaiodobenzylguanidine, Positron emission tomography/computed tomography scan, Planar scintigraphy scan, Single photon emission computed tomography/computed tomography scan
- Drug · Diagnostic Test
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma, Unresectable Meningioma
- Interventions
- Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Computed Tomography, Biospecimen Collection, Single Photon Emission Computed Tomography
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- SPECT/CT
- Diagnostic Test
- Lead sponsor
- BAMF Health
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Hyperparathyroidism
- Interventions
- 99mTc-MIBI planar imaging and SPECT/CT., F- 18PSMA PET/CT imaging study
- Diagnostic Test
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Johns Creek, Georgia
- Conditions
- Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Localized Prostate Carcinoma, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma, Advanced Prostate Cancer, Advanced Prostate Adenocarcinoma
- Interventions
- Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone, PSMA PET-CT Scan, Quality-of-Life Assessment, Single Photon Emission Computed Tomography
- Drug · Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- 99mTc-PYP
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota